143 related articles for article (PubMed ID: 3481241)
21. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
[TBL] [Abstract][Full Text] [Related]
22. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
[TBL] [Abstract][Full Text] [Related]
23. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
24. Immunologic diagnosis and prognosis of human digestive-tract cancer: carcinoembryonic antigens.
Zamcheck N; Moore TL; Dhar P; Kupchik H
N Engl J Med; 1972 Jan; 286(2):83-6. PubMed ID: 4107622
[No Abstract] [Full Text] [Related]
25. [Tumor markers of pancreatic cancer].
Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615
[TBL] [Abstract][Full Text] [Related]
26. [Morphological characteristics of the manifestation of chronic hepatitis and cirrhosis of viral etiology in chronic alcoholics].
Shabanov AM; Domanin AA; Ivanov AA; Lubashevskiĭ VT; Shlinchak NV
Ter Arkh; 1987; 59(7):25-8. PubMed ID: 3672354
[No Abstract] [Full Text] [Related]
27. [CA 19-9, a new tumor marker].
Akai S
Rinsho Byori; 1983 Dec; 31(12):1300-2. PubMed ID: 6587136
[No Abstract] [Full Text] [Related]
28. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences].
Takami H; Hishinuma S; Shintoku J; Ogata Y; Abe O
Gan No Rinsho; 1985 May; 31(6 Suppl):631-7. PubMed ID: 3861883
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of a serum pancreatic tumor marker: the carbohydrate antigen C.A. 19-9].
Vincent D; Venot J; Catanzano G; Clément MN; Piquet MF; Veyriras E; Beck C
Ann Med Interne (Paris); 1985; 136(2):142-4. PubMed ID: 3865571
[TBL] [Abstract][Full Text] [Related]
30. Soluble interleukin-2 receptor: a new marker in pancreatic adenocarcinoma?
Rabitti PG; Pacelli L; Uomo G; Laccetti M; Spada OA; Esposito G; Visconti M
Minerva Gastroenterol Dietol; 1994 Sep; 40(3):101-3. PubMed ID: 7948318
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibody defines CA 19-9 in pancreatic juices and sera.
Schmiegel WH; Kreiker C; Eberl W; Arndt R; Classen M; Greten H; Jessen K; Kalthoff H; Soehendra N; Thiele HG
Gut; 1985 May; 26(5):456-60. PubMed ID: 3858206
[TBL] [Abstract][Full Text] [Related]
32. [Significance of a new tumor marker (CA 19-9) in the differential diagnosis of pathological changes in the pancreas detected by ultrasonic diagnosis].
Bohár L; Szilvási I; Bodorné N; Varsányi N; Barda L; Sarkadi G
Orv Hetil; 1985 Oct; 126(41):2525-7. PubMed ID: 3900874
[No Abstract] [Full Text] [Related]
33. [On pancreatitis of alcoholic etiology].
Losev SI
Vestn Khir Im I I Grek; 1969 Feb; 102(2):28-31. PubMed ID: 5796614
[No Abstract] [Full Text] [Related]
34. Pancreatic oncofoetal antigen in pancreatic cancer.
Hobbs JR; Branfoot AC; Knapp ML
Practitioner; 1980 Oct; 224(1348):1023-7. PubMed ID: 7220429
[No Abstract] [Full Text] [Related]
35. Diagnostic approach to the patient with chronic pancreatic disease and suspected pancreatic carcinoma.
Greenberger NJ
J Kans Med Soc; 1984 Feb; 85(2):53-5, 64. PubMed ID: 6726051
[No Abstract] [Full Text] [Related]
36. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Scheinin TM; Mäkelä O; Jalanko H
Br J Cancer; 1986 Feb; 53(2):197-202. PubMed ID: 3456787
[TBL] [Abstract][Full Text] [Related]
37. Differential diagnosis of pancreatic cancer and chronic pancreatitis by a monoclonal antibody detecting a new cancer-associated antigen (CA 19-9).
Malesci A; Tommasini MA; Bocchia P; Zerbi A; Beretta E; Vecchi M; Di Carlo V
Ric Clin Lab; 1984; 14(3):303-6. PubMed ID: 6522955
[No Abstract] [Full Text] [Related]
38. The use of CA-50 radioimmunoassay in differentiating benign and malignant pancreatic disease.
Habib NA; Hershman MJ; Haberland F; Papp L; Wood CB; Williamson RC
Br J Cancer; 1986 May; 53(5):697-9. PubMed ID: 3459510
[No Abstract] [Full Text] [Related]
39. Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction.
Fabris C; Malesci A; Basso D; Bonato C; Del Favero G; Tacconi M; Meggiato T; Fogar P; Panozzo MP; Ferrara C
Br J Cancer; 1991 Mar; 63(3):451-3. PubMed ID: 2003987
[TBL] [Abstract][Full Text] [Related]
40. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
